Lumida
/ANRO
⌘K
Alto Neuroscience Inc

Alto Neuroscience Inc

ANRO
$32.00USD+1.01%+0.32 today

MARKET CAP

1.3B

P/E (TTM)

FWD P/E

DAY RANGE

$31 – $33

52W RANGE

$4
$37

AI Summary

Stalk
Sell NowMedium

ANRO has decisively broken below short-term EMAs and a prior support cluster on strong volume, confirming continued medium-term bearish control. Short-term momentum is down with price trading below the 9- and 20-day EMAs and RSI trending lower, favoring selling into any rebounds near the broken EMA and support zone. The longer-term uptrend remains intact with price above the 200-day SMA, limiting bearish conviction and signaling that rallies may provide optimal entry points for further selling.

  • Stock gained 9.2% over past two weeks, signaling strong momentum factors.
  • “Moderate Buy” consensus with $36.63 target implies 25.8% upside.
  • EPS expected to fall from ($3.14) to ($3.56), indicating financial strain.
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
May 14, 2026SellANROAmit EtkinPRESIDENT AND CEO400,000$23.59$1.3B-14.62%+791.36%$9.4M-32.42%Buy Now
Mar 1, 2026SellANRONicholas Conrad SmithCHIEF FINANCIAL OFFICER & CBO2,806$19.69$1.3B-14.62%+791.36%$55.3K-10.44%Buy Now
Mar 1, 2026SellANROAmit EtkinPRESIDENT AND CEO6,227$19.69$1.3B-14.62%+791.36%$122.6K-0.50%Buy Now
Jul 9, 2024BuyANROAdam SavitzCHIEF MEDICAL OFFICER15,000$12.72$1.3B-14.62%+791.36%$190.8K+15.42%Buy Now
Mar 28, 2024BuyANRONicholas Conrad SmithCHIEF FINANCIAL OFFICER6,150$16.36$1.3B-14.62%+791.36%$100.6K+14.29%Buy Now
Feb 6, 2024BuyANRONicholas Conrad SmithCHIEF FINANCIAL OFFICER1,563$16.00$1.3B-14.62%+791.36%$25.0KBuy Now
Feb 6, 2024BuyANROAmit EtkinPRESIDENT AND CEO3,125$16.00$1.3B-14.62%+791.36%$50.0K+0.26%Buy Now
Feb 6, 2024BuyANROAdam SavitzCHIEF MEDICAL OFFICER17,000$16.00$1.3B-14.62%+791.36%$272.0K+216.53%Buy Now